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Summary Clinical effects and pharmacokinetics of once-a-day pediatric zonisamide
(ZNS) monotherapy were investigated in 72 children (range, 3 months to 15 years;
mean age, 8 years and 3 months) with cryptogenic localization-related epilepsies with
simple, complex, or secondarily generalized partial seizures; none had prior epilepsy
treatment. ZNS was initiated at 2mg/kg; daily dosage was doubled at weekly intervals
to achieve maintenance dosage (8.0mg/kg; mean, 7.97 ± 0.55mg/kg). Blood sam-
ples determined trough and peak plasma levels; levels were 27.0 ± 9.4g/ml and
33.8 ± 10.8g/ml, respectively, with ratios as small as 1.28 ± 0.15. Plasma level to
dose ratios increased with age; peak-to-trough ratios were not age variable. Seizures
were not controlled in 23 of 72 patients; low trough plasma levels (approximately
15g/ml) were observed. Drowsiness/short attention span in ﬁve patients instigated
a dosage decrease (peak plasma levels >40g/ml). During treatment (6–43 months;
mean, 27.2 months), seizure control occurred in 57 of 72 patients (79.2%), including
eight refractory patients. In 12 patients with uncontrolled seizures and high ZNS lev-
els, carbamazepine (CBZ) was added (BID; mean total dose, 15.1 ± 3.0mg/kg) to ZNS
(QD; mean dose, 11.1 ± 2.5mg/kg); drug interactions were examined.
© 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.
Introduction
Zonisamide, an antiepilepsy drug (AED) developed
in Japan, was shown to have strong inhibitory ef-
fects on convulsions of cortical origin in animal stud-
ies by suppressing both focal spiking and the spread
of secondarily generalized seizures induced by elec-
tric or chemical stimuli.1,2 Clinical studies have re-
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vealed that zonisamide is effective in most types
of epileptic seizures, especially for the control of
partial seizures.3—6
Zonisamide is absorbed slowly from the gastroin-
testinal tract, and its biological half-life is long
compared to other prevalent AEDs. Pilot studies
indicate that peak plasma concentrations of zon-
isamide occur approximately 4 to 6 h after dosing,
and that its half-life is long–—up to 60 h in adult
volunteers.4,7
Based on these pharmacokinetic characteristics,
we investigated the clinical effects and plasma
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levels of zonisamide in a prospective randomized
study where zonisamide was administered once a
day as monotherapy to children with cryptogenic
localization-related epilepsies.
Materials and methods
Patients comprised 72 children, ages 3 months to
15 years (mean, 8 years and 3 months) with par-
tial seizures, who had not previously received treat-
ment for epilepsy, and were newly referred to our
pediatric seizure clinic. All patients were classiﬁed
as having cryptogenic localization-related epilep-
sies, and all had experienced two or more seizures
before starting zonisamide monotherapy. Four pa-
tients had simple partial seizures, 23 had complex
partial seizures, and 45 had partial seizures evolv-
ing to secondarily generalized seizures (Table 1). No
patients showed evidence of mental retardation or
other associated neuropsychiatric handicaps.
Patients received zonisamide at a starting daily
dose of 2mg/kg, in order to avoid initial side ef-
fects of drowsiness and ataxic gait. The dosage was
then doubled at weekly intervals until an initial
maintenance daily dose of 8mg/kg (mean, 7.97 ±
0.55mg/kg per day) was reached. Zonisamide was
prescribed once a day, in the morning.
Pharmacokinetic data were obtained 4 weeks af-
ter starting the maintenance dosage. To determine
trough plasma levels of zonisamide in a day, blood
samples were taken prior to the morning dose;
to determine peak levels, blood samples were
taken 4 h after the morning dose. Subsequently,
plasma levels were determined every 6 months,
Table 1 Patient characteristics.
Age
Mean: 8 years and 3 months Range: 3 months to 14
years and 11 months
Seizure classiﬁcation Simple partial (n = 4), complex partial
(n = 23), simple/complex evolving to
secondarily generalized (n = 45)
Initial maintenance dosage Mea ± S.D.: 7.97 ± 0.55mg/kg per day Range: 5.82—10.19mg/kg per day
Duration of follow-upa Mean: 27.2 months Range: 6—43 months
a Excluding 15 cases in whom zonisamide monotherapy was discontinued because of seizure recurrences.
Table 2 Characteristics of patients receiving zonisamide monotherapy, and then zonisamide combined with
carbamazepine (n = 12).
Age
Mean: 12 years and 1 month Range: 5—16 years
Dosage (mean ± S.D.) ZNS: 11.1 ± 2.5mg/kg per day CBZ: 15.1 ± 3.0mg/kg per day
and more often as necessary. Determination of
plasma levels of zonisamide was performed using
high-performance liquid chromatography (HPLC).
Among patients whose seizures could not be con-
trolled by zonisamide monotherapy, even by ad-
justing dosage and maintaining high plasma lev-
els, carbamazepine was added and drug interac-
tions between zonisamide and CBZ were investi-
gated. The effects of CBZ on seizure control were
also observed.
These 12 patients, who were 5 to 16 years old
(mean age, 12 years and 1 month), received zon-
isamide once daily in the morning (mean daily dose,
11.1 ± 2.5mg/kg), and CBZ twice daily: once in
the morning and once in the evening (mean daily
dose, 15.1 ± 3.0mg/kg) (Table 2). After combi-
nation therapy with zonisamide and CBZ for 6 to
12 months, 9 of the 12 patients discontinued zon-
isamide, switching to CBZ monotherapy (Table 3).
Blood samples for determination of plasma concen-
trations of zonisamide, CBZ, and its main metabo-
lite, carbamazepine-10,11-epoxide (CBZ-E), were
taken before, and 4 h after the morning dose; each
represented trough and peak levels of zonisamide
and CBZ in a day, respectively. Plasma concentra-
tions of CBZ and CBZ-E were determined by HPLC.
Results
Phase I: clinical effects and plasma levels of
zonisamide monotherapy
Initial maintenance daily doses of zonisamide
(mean, 7.97 ± 0.55mg/kg) yielded trough plasma
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Table 3 Characteristics of patients receiving zonisamide combined with carbamazepine, and then carbamazepine
monotherapy (n = 9).
Age
Mean: 11 years and 6 months Range: 5—16 years
Dosage (mean ± S.D.) ZNS: 11.1 ± 2.8mg/kg per day CBZ: 15.8 ± 2.9mg/kg per day
levels of 27.0 ± 9.4g/ml and peak plasma levels
of 33.8 ± 10.8g/ml. Peak-to-trough plasma level
ratios were as small as 1.28 ± 0.15 (Table 4). Ra-
tios of plasma level (g/ml) to dose (mg/kg per
day), estimated by trough and peak plasma levels,
increased for both with increasing age (Fig. 1);
however, peak-to-trough plasma level ratios were
maintained almost uniformly throughout the pedi-
atric age period (Fig. 2).
Clinical effects were then investigated with ref-
erence to plasma levels of zonisamide. Of the 72
total patients, seizures were not controlled with
the initial maintenance dosage in 23 patients, and
recurred within 6 months after administration of
zonisamide. Many of the patients who showed low
trough plasma levels of zonisamide (approximately
15g/ml) had seizure recurrences. In ﬁve patients
whose peak plasma levels of zonisamide exceeded
40g/ml, daily doses were decreased to tolerable
levels because of continuous complaints of drowsi-
ness in four patients and short attention span in one
patient.
Zonisamide monotherapy was discontinued early
in two patients because of frequent seizure recur-
rences. Dosage increment was difﬁcult in one pa-
tient because of the behavioral side effect of short
attention span. In one patient whose seizures were
not controlled despite high peak plasma levels of
zonisamide, CBZ was combined with zonisamide
immediately after seizure recurrences. In another
patient whose seizures recurred only with fever,
rectal diazepam suppositories were given intermit-
tently at the time of febrile illness to control these
seizures.
Table 4 Daily ﬂuctuations in plasma zonisamide
level in patients receiving zonisamide monotherapy (n
= 72).
Plasma level
Mean ± S.D. Range
Trough level (g/ml) 27.0 ± 9.4 10.2—49.1
Peak level (g/ml) 33.8 ± 10.8 12.7—65.5
Peak/trough ratio 1.28 ± 0.15 0.98—1.66
In 10 patients whose seizures recurred with the
initial maintenance dosage, seizures were not con-
trolled even after increasing the dosage. In eight
patients, however, seizure control could be at-
tained by increasing the daily dose of zonisamide,
as shown in Fig. 3. This brought the total number
of patients whose seizures were controlled on zon-
isamide monotherapy to 57 of 72 patients (79.2%)
over a period of treatment ranging from 6 to 43
months (mean, 27.2 months).
Fig. 4 shows relationships between trough and
peak plasma levels of zonisamide at the initial main-
Figure 1 Relationship between age and ratios of plasma
level to dose in patients receiving zonisamide monother-
apy.
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Figure 2 Relationship between age and ratios of peak-to-trough plasma levels in patients receiving zonisamide
monotherapy.
tenance dosage, and clinical effects for patients in
three age groups (3 months to 6 years, 6 to 12 years,
and 12 to 15 years). Generally, plasma levels in-
creased with age, but there was no clear relation-
ship between plasma levels and seizure control in
each age group.
Side effects observed with zonisamide treatment
included drowsiness (13 patients) and short atten-
tion span (2 patients). Most of the adverse effects
were transient, but daily doses were decreased
to more tolerable levels due to persistent prob-
lems with drowsiness in four patients and short
attention span in one patient. Loss of appetite
Figure 3 Plasma levels of zonisamide in relation to dosage increases and clinical effects in 18 patients whose seizures
were not controlled on initial maintenance dosage.
appeared transiently in two patients after start-
ing the therapy. In addition, one patient had a
rash and agranulocytosis at an early stage of the
therapy, and another patient had to be returned
to his initial maintenance daily dosage of 4mg/kg
because of continuous complaints of drowsiness;
both were excluded from this study. A 6-year-old
female patient showed decreased high cerebro-
cortical activity and mental slowing soon after
starting the zonisamide therapy; these complaints
disappeared after the therapy was discontinued.
This patient was also excluded from the study
group.
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Table 5 Effect of concurrent administration of carbamazepine on plasma concentrations of zonisamide (n = 12).
Medication
ZNS monotherapy ZNS + CBZ
ZNS trough level (g/ml) 35.4 ± 10.0 22.2 ± 9.8∗
ZNS peak level (g/ml) 43.0 ± 11.3 28.1 ± 12.5∗
Peak/trough ratio 1.23 ± 0.12 1.29 ± 0.22
∗ P < 0.05 (Wilcoxon T).
Phase II: interactions between zonisamide
and CBZ
With the addition of CBZ in 12 patients, trough and
peak plasma levels of zonisamide decreased from
35.4 ± 10.0g/ml to 22.2 ± 9.8g/ml, and from
43.0 ± 11.3g/ml to 28.1 ± 12.5g/ml, respec-
tively (Table 5). Plasma levels of CBZ and CBZ-E
Figure 4 Plasma levels of zonisamide in relation to age and clinical effects on initial maintenance dosage.
before the morning dose were 6.05 ± 1.98g/ml
and 1.32 ± 0.23g/ml, and those 4 h after the
morning dose were 9.06 ± 2.83g/ml and 1.61 ±
0.35g/ml, respectively. Fig. 5 shows the effect
of concurrent administration of CBZ on the plasma
concentrations of zonisamide in individual patients.
After combination therapy with zonisamide and
CBZ, drug therapy was changed to CBZ monother-
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Figure 5 Effect of concurrent administration of carbamazepine on plasma concentrations of zonisamide.
Table 6 Effects of concurrent administration of zonisamide on plasma concentrations of carbamazepine (CBZ)
and its epoxide metabolite (CBZ—E) (n = 9).
Medication
ZNS + CBZ CBZ monotherapy
CBZ
Trough level (g/ml)a 6.05 ± 1.98 6.52 ± 2.06
Peak level (g/ml)b 9.06 ± 2.83 9.24 ± 1.91
Peak/trough ratio 1.52 ± 0.24 1.46 ± 0.23
CBZ-E
Trough level (g/ml)a 1.32 ± 0.23 1.15 ± 0.19
Peak level (g/ml)b 1.61 ± 0.35 1.50 ± 0.27
a Levels before morning dose.
b Levels 4 h after morning dose.
apy in 9 of the 12 patients. Comparison of plasma
levels of CBZ and CBZ-E in these patients be-
fore and after discontinuation of zonisamide re-
vealed no signiﬁcant differences when CBZ was
used alone or in combination with zonisamide
(Table 6).
In 6 of the 12 patients whose seizures were not
controlled with zonisamide monotherapy, com-
plete seizure control was obtained after addition
of CBZ for a period ranging from 7 to 33 months
(mean, 24 months). In three of the remaining
six patients whose seizures were not controlled
with both zonisamide and CBZ, seizures were ﬁ-
nally controlled after administration of sodium
valproate in two patients, and clonazepam in one
patient.
Discussion
Zonisamide is absorbed slowly from the gastroin-
testinal tract, and its biological half-life is long
compared to other common AEDs. Studies4,7,8 in
adult volunteers indicate that the plasma concen-
tration of zonisamide peaks 4 to 6 h after dosing,
and that its half-life is as long as 60 h. We inves-
tigated the clinical effects and pharmacokinetics
of zonisamide given once a day as monotherapy
in children with cryptogenic localization-related
epilepsies.
In this study, peak-to-trough plasma level ra-
tios during the day were as small as 1.28 ± 0.15
in children taking an initial maintenance daily
dose of 8.0 ± 0.6mg/kg once a day as monother-
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apy. This ﬁnding was similar to that observed
recently in healthy adult volunteers.8 Plasma
level (g/ml) to dose (mg/kg per day) ratios es-
timated by trough and peak levels both increased
with advancing age, but peak-to-trough plasma
level ratios were maintained almost uniformly
throughout the pediatric age period. Zonisamide
may show nonlinear pharmacokinetics resembling
that of phenytoin.9 This, however, would not be
substantiated within the range of generally ac-
cepted therapeutic dosage and therapeutic plasma
levels.
Although plasma levels varied widely among pa-
tients who became seizure free with zonisamide
monotherapy, and the ﬁnal range of plasma lev-
els, after increasing the dosage among patients who
did not respond to zonisamide, was high relative
to those whose seizures were controlled, the ulti-
mate clinical effects observed were consistent with
the range of therapeutic plasma levels generally ac-
cepted for zonisamide, that is, 15 to 40g/ml.3,4
It has been suggested that impairments of high
cerebrocortical function, such as decreased spon-
taneity or memory, are seen in some patients tak-
ing zonisamide combined with many other AEDs.3
However, these adverse effects were not seen in
our patients treated with zonisamide monotherapy,
except for one patient who was excluded from the
study group.
Zonisamide is widely approved as an adjunctive
drug for partial seizures. The ﬁndings presented
here suggest that zonisamide is also effective as
monotherapy for partial seizures in children and
can provide effective control when taken once
daily, which should enhance patient compliance
with treatment. However, an initial maintenance
dose of zonisamide should be determined based
not only on weight but also age, because ratios of
plasma zonisamide levels (g/ml) to dose (mg/kg
per day) increase with age.
For patients whose seizures are not controlled
by zonisamide, CBZ can be added with some suc-
cess. Any patient who receives polytherapy is at
risk to develop one or more drug interactions. As
expected based on zonisamide metabolism by cy-
tochrome P450 enzymes, CBZ reduces both peak and
trough levels of zonisamide. However, zonisamide
does not alter plasma levels of CBZ and CBZ-E. CBZ
is extensively metabolized to its active metabo-
lite, CBZ-E, and ﬁnally to an inactive metabolite,
10,11-dihydroxycarbamazepine.
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